Patents by Inventor Jianyi Zhang

Jianyi Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250134917
    Abstract: Disclosures herein are directed to methods of regenerating cardiomyocytes in heart tissue damaged as a result heart failure in a subject by administering one or more aminoglycosides to a subject in need thereof. Accordingly, disclosures herein are also toward methods of administering one or more aminoglycosides to treat heart failure in a subject in need thereof.
    Type: Application
    Filed: January 20, 2023
    Publication date: May 1, 2025
    Inventors: Hesham A. Sadek, Ngoc Uyen Nhi Nguyen, Mahmoud Salama Ahmed, Diana Tomchick, Jianyi Zhang
  • Publication number: 20250020633
    Abstract: Herbal or Traditional Chinese Medicine (TCM) is often mixed with multiple compounds. The effect may be from one or a few compounds, the reactants of several compounds, or the metabolism and reactants of the compound compounds in the body. Therefore, it is impossible to determine what bioactive compounds is/are by the traditional method. In this method, herbals are used to treat patients and blood specimens are collected and subjected to chemical analysis. Common chemical elements are identified from patients who respond well to the herbals, and the common elements will be matched with elements from poorly responsive patients to find out which elements were missed. Adding missed elements and treating the poorly responsive patients, if the treated patients respond well, the common elements are bioactive ones.
    Type: Application
    Filed: July 16, 2023
    Publication date: January 16, 2025
    Inventor: Jianyi Zhang
  • Patent number: 12156918
    Abstract: A majority of neuroendocrine (NE) cancers overexpress somatostatin receptors (SSTRs). Disclosed herein are anti-SSTR2 monoclonal antibodies, and antibody-drug conjugates (ADCs) for use as NE cancer targeting therapeutics. Also disclosed is an isolated nucleic acid encoding the disclosed antibodies, as well as nucleic acid vectors containing this isolated nucleic acid operably linked to an expression control sequence. Also disclosed are cells transfected with these vectors and the use of these cells to produce the disclosed recombinant antibodies. Also disclosed is a method of treating a neuroendocrine (NE) cancer in a subject, comprising administering to the subject an effective amount of the disclosed antibody conjugated to an anti-cancer agent.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: December 3, 2024
    Assignee: The UAB Research Foundation
    Inventors: Xiaoguang Liu, Lufang Zhou, Jianfa Ou, Yingnan Si, Renata Jaskula-Sztul, Herbert Chen, Jason Derek Whitt, Jianyi Zhang
  • Patent number: 12088224
    Abstract: A finite time speed control method for a permanent magnet synchronous motor (PMSM) based on a fast integral terminal sliding mode and disturbance estimation comprises: firstly, determining a mathematical model of a speed loop of the PMSM under the influence of system parameters uncertainty and unknown load torque; secondly, designing an improved fast integral terminal sliding surface on the basis of the idea of terminal sliding mode control; then, proposing a disturbance estimation method based on an adaptive fuzzy system with respect to the disturbance in a PMSM system; designing a PMSM speed controller on this basis; and finally, completing the concrete implementation of the whole technical solution. The present invention designs the fast integral terminal sliding surface and a sliding mode control law to ensure that a motor speed tracking error converges to zero within finite time and enhances the rapidity of a PMSM speed regulating system.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: September 10, 2024
    Assignee: DALIAN UNIVERSITY OF TECHNOLOGY
    Inventors: Ximing Sun, Jianyi Zhang
  • Publication number: 20240254052
    Abstract: The invention relates to a method for preparing ceramic material of ceramic electrode for tumor treating fields, which comprises the following steps of: synthesizing a[0.67Bi0.995Ce0.005FeO3?0.33BaTiO3]?b[Sr1-xPbxTi1?yZryO3]?c[Pb(Mg1/3Nb2/3)O3] powder by a solid phase method; Where 0<a<0.06, 0.05<b<0.18, a+b+c=1; 0.6?x?0.8, 0<y<0.2; Fine grinding the powder, adding a binder, granulating, and pressing for forming to obtain a biscuit; Removing organic substances in the biscuit; Sinter that biscuit to obtain the ceramic material. The invention also provides a ceramic material prepared by the preparation method, which has the characteristics of high dielectric constant and low loss and is suitable for manufacturing a ceramic capacitor electrode for conducting an electric field but blocking conducting current.
    Type: Application
    Filed: March 1, 2024
    Publication date: August 1, 2024
    Inventors: Jianyi Zhang, Shengjun Liu, Hongjie Duan
  • Publication number: 20240026297
    Abstract: Disclosed herein is a simple and reproducible 3D-culture-based process for generating cardiac spheroids containing all four cardiac-cell types (cardiomyocytes, endothelial cells, smooth muscle cells, and cardiac fibroblasts) that is compatible with a wide range of applications and research equipment. Subsequent experiments demonstrated that the inclusion of vascular cells and cardiac fibroblasts was associated with an increase in spheroid size, a decline in apoptosis, an improvement in sarcomere maturation and a change in CM bioenergetics. These suggest a three-dimensional (3D) environment with endothelial cells, smooth muscle cells, and cardiac fibroblasts which promoted CM maturation and electrical activity.
    Type: Application
    Filed: July 13, 2023
    Publication date: January 25, 2024
    Inventors: Asher Max Kahn-Krell, Jianyi Zhang
  • Publication number: 20230364267
    Abstract: In one aspect, the disclosure relates to a synthetic modified mRNA (modRNA) and a novel gene therapy approach using the same that offers efficient, transient, safe, nonimmunogenic, and controlled mRNA delivery to the heart tissue without any risk of genomic integration. In a further aspect, the disclosure relates to methods of using the modRNA to achieve transient and exclusive overexpression of CCND2 only in cardiomyocytes, increasing cell cycle markers, enhancing cardiac function, and promoting myocardial repair. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 16, 2023
    Inventors: Jianyi Zhang, Yang Zhou, Jiacheng Sun, Lu WANG
  • Publication number: 20230246578
    Abstract: A finite time speed control method for a permanent magnet synchronous motor (PMSM) based on a fast integral terminal sliding mode and disturbance estimation comprises: firstly, determining a mathematical model of a speed loop of the PMSM under the influence of system parameters uncertainty and unknown load torque; secondly, designing an improved fast integral terminal sliding surface on the basis of the idea of terminal sliding mode control; then, proposing a disturbance estimation method based on an adaptive fuzzy system with respect to the disturbance in a PMSM system; designing a PMSM speed controller on this basis; and finally, completing the concrete implementation of the whole technical solution. The present invention designs the fast integral terminal sliding surface and a sliding mode control law to ensure that a motor speed tracking error converges to zero within finite time and enhances the rapidity of a PMSM speed regulating system.
    Type: Application
    Filed: May 6, 2021
    Publication date: August 3, 2023
    Inventors: Ximing SUN, Jianyi ZHANG
  • Patent number: 11695358
    Abstract: A speed control method for a permanent magnet synchronous motor considering current saturation and disturbance suppression aims to effectively ensure that a current of the motor is always within a given range to avoid the problem of control performance reduction caused by the fact that the current gets into a saturation state, ensure the safety of a system, do not need to use unavailable state variables such as motor acceleration and the like, effectively estimate and compensate disturbances including parameters uncertainty and unknown load torque disturbance existing in a permanent magnet synchronous motor system, and rapidly and accurately control a speed of the motor finally. There is no need to configure a plurality of sensors in practical industrial application, so system building costs can be reduced on the one hand, and the stability of the system can be improved on the other hand.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: July 4, 2023
    Assignee: DALIAN UNIVERSITY OF TECHNOLOGY
    Inventors: Ximing Sun, Jianyi Zhang
  • Publication number: 20230129137
    Abstract: In one aspect, the disclosure relates to nanoparticle compositions including TT-10 or a pharmaceutically acceptable salt thereof and nanoparticles including at least one biocompatible polymer or copolymer such as poly-lactic-co-glycolic acid. Also disclosed are methods for improving at least one cardiac function or property following heart damage in a subject, the methods including at least the step of administering the nanoparticle compositions to the subject. In another aspect, the nanoparticle compositions can be administered by intraperitoneal injection and are active at a target site for a period of at least 4 weeks.
    Type: Application
    Filed: October 18, 2022
    Publication date: April 27, 2023
    Inventors: Jianyi Zhang, Yang Zhou
  • Patent number: 11594991
    Abstract: A robust position control method for a permanent magnet synchronous motor considering current limitation is provided. The method fully considers the influence of current limitation on a closed loop system in controller design, stability analysis and other theoretical analysis phase, can effectively overcome the influence of system disturbances including system parameters uncertainty and unknown load torque, and finally realize a control objective of accurate tracking of the motor position. More importantly, the technology is a continuous control method which can overcome the inherent chattering problem while having strong robustness of sliding mode control. Meanwhile, a controller designed by the present invention also has the advantages of simple structure, etc. The technical solution proposed by the present invention has wide practical application prospect due to the characteristics of excellent anti-disturbance capability, and simple and feasible structure.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: February 28, 2023
    Assignee: DALIAN UNIVERSITY OF TECHNOLOGY
    Inventors: Ximing Sun, Jianyi Zhang
  • Publication number: 20230048547
    Abstract: A robust position control method for a permanent magnet synchronous motor considering current limitation is provided. The method fully considers the influence of current limitation on a closed loop system in controller design, stability analysis and other theoretical analysis phase, can effectively overcome the influence of system disturbances including system parameters uncertainty and unknown load torque, and finally realize a control objective of accurate tracking of the motor position. More importantly, the technology is a continuous control method which can overcome the inherent chattering problem while having strong robustness of sliding mode control. Meanwhile, a controller designed by the present invention also has the advantages of simple structure, etc. The technical solution proposed by the present invention has wide practical application prospect due to the characteristics of excellent anti-disturbance capability, and simple and feasible structure.
    Type: Application
    Filed: January 7, 2021
    Publication date: February 16, 2023
    Inventors: Ximing SUN, Jianyi ZHANG
  • Publication number: 20220311366
    Abstract: The present invention belongs to the technical field of permanent magnet synchronous motor control, and provides a speed control method for a permanent magnet synchronous motor considering current saturation and disturbance suppression, which aims to effectively ensure that a current of the motor is always within a given range to avoid the problem of control performance reduction caused by the fact that the current gets into a saturation state, ensure the safety of a system, do not need to use unavailable state variables such as motor acceleration and the like, effectively estimate and compensate disturbances including parameters uncertainty and unknown load torque disturbance existing in a permanent magnet synchronous motor system, and rapidly and accurately control a speed of the motor finally. There is no need to configure a plurality of sensors in practical industrial application, so system building costs can be reduced on the one hand, and the stability of the system can be improved on the other hand.
    Type: Application
    Filed: October 27, 2020
    Publication date: September 29, 2022
    Inventors: Ximing SUN, Jianyi ZHANG
  • Publication number: 20210340264
    Abstract: A majority of neuroendocrine (NE) cancers overexpress somatostatin receptors (SSTRs). Disclosed herein are anti-SSTR2 monoclonal antibodies, and antibody-drug conjugates (ADCs) for use as NE cancer targeting therapeutics. Also disclosed is an isolated nucleic acid encoding the disclosed antibodies, as well as nucleic acid vectors containing this isolated nucleic acid operably linked to an expression control sequence. Also disclosed are cells transfected with these vectors and the use of these cells to produce the disclosed recombinant antibodies. Also disclosed is a method of treating a neuroendocrine (NE) cancer in a subject, comprising administering to the subject an effective amount of the disclosed antibody conjugated to an anti-cancer agent.
    Type: Application
    Filed: October 8, 2019
    Publication date: November 4, 2021
    Inventors: Xiaoguang Liu, Lufang Zhou, Jianfa Ou, Yingnan Si, Renata Jaskula-Sztul, Herbert Chen, Jason Derek Whitt, Jianyi Zhang
  • Publication number: 20210205475
    Abstract: Disclosed herein is an optogenetics-based gene therapy that involves channelrhodopsin fusion proteins having an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS) that can effectively target the fusion protein to an inner mitochondria membrane, and a channelrhodopsin ion channel domain that can change the mitochondrial membrane potential (??m) when light is present. The disclosed optogenetics-based gene therapy system can in some embodiments further involve luciferase fusion proteins to stimulate the channelrhodopsin without reliance on external light that has an outer mitochondrial membrane-mitochondrial localization signal (OMM-MLS) that can effectively target the luciferase fusion protein to an outer mitochondrial membrane, and a luciferase protein that can produce a bioluminescence in the presence of a luciferase substrate.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 8, 2021
    Inventors: Xiaoguang Liu, Lufang Zhou, Jianyi Zhang, Patrick James Ernst, Ningning Xu
  • Publication number: 20190314431
    Abstract: The invention discloses a method by which potential bioactive compounds from herbals can be identified by regrouping after chromatography. The method comprises the steps of: selecting herbals with reports of therapeutic effects according to previous experience, extracting compounds by boiling or chemical methods, and separating compounds with the chromatography. The separated compounds are regrouped with different portions, which are further tested in vivo and/or in vitro to remove the inactive portions and repeating the same process until no more compounds can be removed, and the remaining compounds are synthesized or purified, which are made into various forms and utilized to treat diseases.
    Type: Application
    Filed: January 25, 2019
    Publication date: October 17, 2019
    Inventor: Jianyi Zhang
  • Patent number: 9709649
    Abstract: A system and method for acquiring and using inversion-recovery data and spectral data. In particular, the inversion-recovery data and spectral data can be used to determine adenosine triphosphate (ATP) hydrolysis rate of a subject without a quantification of inorganic phosphate.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: July 18, 2017
    Assignee: Regents of the University of Minnesota
    Inventors: Qiang Xiong, Jianyi Zhang
  • Publication number: 20160113939
    Abstract: The invention discloses a method of treatment for various severe disorders which is not treated well by current FDA approved drugs. The therapeutic agents by the method are compounds or biological agents which pass safety tests in the clinical trials, but not pass the efficacy test, as safety of those compounds or biological agents are comparable with any ones in the market which pass both safety and efficacy tests in the clinical trials, combined application of those compounds or biological agents can significantly improve varied severe medical conditions.
    Type: Application
    Filed: January 1, 2016
    Publication date: April 28, 2016
    Inventor: Jianyi Zhang
  • Publication number: 20160085941
    Abstract: A method of proving safety and efficacy of herbal compounds by clinical information obtained by physicians in daily practice by implementation of network technology, chemical analysis, statistics, and clinical trials. Data for potential therapeutic compounds are directly obtained from human being in daily practice setting, application of the invention will tremendously reduce the time and costs involved in research and development of drugs.
    Type: Application
    Filed: September 26, 2015
    Publication date: March 24, 2016
    Inventor: Jianyi Zhang
  • Publication number: 20140225609
    Abstract: A system and method for acquiring and using inversion-recovery data and spectral data. In particular, the inversion-recovery data and spectral data can be used to determine adenosine triphosphate (ATP) hydrolysis rate of a subject without a quantification of inorganic phosphate.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Inventors: Qiang Xiong, Jianyi Zhang